RPS6KA1 and acute myeloid leukemia: Patients with higher levels of phosphorylated RSK (T573) had significantly shorter complete remission duration (p = 0.031) and worse event free survival (p = 0.047) (Figure 1C and 1D), suggesting hyperactivated RSK could be a drug target for AML therapy.